JPMorgan Chase & Co. Cuts Position in Pediatrix Medical Group, Inc. (NYSE:MD)

JPMorgan Chase & Co. reduced its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 5.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 942,312 shares of the company’s stock after selling 59,509 shares during the quarter. JPMorgan Chase & Co.’s holdings in Pediatrix Medical Group were worth $10,921,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Quest Partners LLC increased its stake in shares of Pediatrix Medical Group by 25.6% in the third quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock worth $35,000 after buying an additional 622 shares during the last quarter. Quarry LP boosted its position in shares of Pediatrix Medical Group by 54.1% during the third quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after buying an additional 1,662 shares during the period. Canada Pension Plan Investment Board bought a new position in Pediatrix Medical Group in the 2nd quarter valued at about $72,000. CWM LLC lifted its position in Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after purchasing an additional 3,681 shares during the period. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Pediatrix Medical Group during the second quarter valued at about $81,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of Pediatrix Medical Group stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on MD. Jefferies Financial Group increased their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft upped their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Mizuho raised their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Macquarie assumed coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, UBS Group lifted their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Trading Down 2.1 %

Pediatrix Medical Group stock opened at $12.46 on Monday. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -4.07, a PEG ratio of 2.00 and a beta of 1.58. The company’s fifty day moving average price is $14.30 and its two-hundred day moving average price is $11.62. Pediatrix Medical Group, Inc. has a one year low of $6.62 and a one year high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same period in the previous year, the business posted $0.29 EPS. The company’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts forecast that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.